Document is current
Any future updates will be listed below
-
Authors
Wang, Shuangshou https://orcid.org/0000-0001-5255-8530
Ding, Yuwen
Wang, Haili
Li, Wenzhi
Xu, Wenjing
Sun, Panwen
Huang, Wei
Chen, Yang
Gu, Jing
Lin, Peng
Ma, Liang
Liu, Zi
Ling, Qiang
Zhang, Qi
Chen, Hongmei
Yan, Tingxuan
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (21904003)
Natural Science Foundation of Anhui Province (1908085QB66, 1908085MF197, 2108085QB85)
Key Project of Research and Development of Bengbu (BYLK201809)
Student Research Training Program of Anhui University of Technology (202110360034, S202110360202)
Open Project of Anhui Engineering Technology Research Center of Biochemical Pharmaceutical (2022SYKFZ02)
- License Information
-
More Information
Article History
Received: 5 January 2022
Accepted: 28 January 2022
First Online: 17 February 2022
Declarations
:
: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
: Male SPF mice with 4 ~ 6 weeks old and 20 ~ 25 g of body weight for each were served as model animals in this work; tumors were established by subcutaneous injection of HepG2 cells in the right axilla of each SPF mouse. All animals were maintained in a pathogen-free environment and fed ad lib for 3 days before starting the experiments. No significant adverse effects were observed during the research, and all animals were euthanized at the end of the experiments. The procedures for care and use of animals were approved by the Animal Care and Use Committee of Bengbu Medical College (number of animal license: SYXK(皖) 2017-001) and performed in line with the guidelines of the Declaration of Helsinki. All applicable institutional and governmental regulations concerning the ethical use of animals were followed.
